Adial Pharmaceuticals announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office. The patent covers the Company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADIL:
- Two new option listings and option delistings on February 26th
- Biotech Alert: Searches spiking for these stocks today
- Adial sees patent award boosting partnering efforts, says Brookline
- Adial Pharmaceuticals awarded patent notice of allowance for USPTO
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
